000 01705nam  22003018a 4500
0019.865656
003CaOODSP
00520190121153602
007cr |||||||||||
008181205t20192014onc    go    f000 0 eng d
020 |a9780660288628
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-243/2018E-PDF
24500|aLiterature review on the immunogenicity of herpes zoster vaccines |h[electronic resource].
260 |a[Ottawa] : |bPublic Health Agency of Canada, |c2019.
300 |a46 p.
500 |aIssued also in French under title: Revue de la littérature sur l'immunogénicité des vaccins contre le zona.
500 |a"Publication date: January 2019."
500 |a"An Advisory Committee Review (ACR), National Advisory Committee on Immunization (NACI)."
500 |aCover title.
504 |aIncludes bibliographical references.
516 |aElectronic monograph in PDF format.
520 |a"Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines"--Executive summary, p. 3.
69207|2gccst|aImmunization
7101 |aCanada. |bPublic Health Agency of Canada.
77508|tRevue de la littérature sur l'immunogénicité des vaccins contre le zona |w(CaOODSP)9.865657
85640|qPDF|s1.56 MB|uhttp://publications.gc.ca/collections/collection_2019/aspc-phac/HP40-243-2018-eng.pdf